Factors associated with uptake of Haemophilus influenzae type b vaccination in Shanghai, China.
Completion
Coverage
Haemophilus influenzae type b vaccine
Timeliness
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
07 01 2019
07 01 2019
Historique:
received:
13
06
2018
accepted:
18
12
2018
entrez:
9
1
2019
pubmed:
9
1
2019
medline:
20
2
2020
Statut:
epublish
Résumé
Haemophilus influenzae type b (Hib) vaccine is effective in reducing the burden of Hib related diseases, but little is known about factors influencing the uptake of Hib vaccine. This study aimed to assess the uptake of Hib vaccination and its associated factors in Shanghai City, China. We used data from a retrospective cohort of 183,246 children born in 2012-2016 obtained from the Shanghai Immunization Program Information System, which provided information on the uptake of Hib vaccination. We conducted a cross-sectional study of 451 children to collect information on demographic and other factors that might be associated with Hib vaccination. In the retrospective cohort study, the proportions of Hib dose-1 coverage, vaccination completion and timeliness were 67.7, 52.2 and 29.4%, respectively. These measures were better among local children and increased with birth year, while there were regional differences. Hib vaccine uptake was significantly associated with maternal occupation (non-health vs health workers, OR = 2.33, 95% CI: 1.32-4.13, P = 0.004) and caregivers' awareness of Hib (yes vs no, OR = 1.75, 95% CI: 1.12-2.74, P = 0.013). We found low levels of coverage of dose-1 Hib vaccine, timeliness and completion, suggesting inadequate protection against Hib disease for children in Shanghai. Non-local children and those of health workers should be targeted for interventions. The inclusion of Hib vaccine into the national immunization program could help improve the uptake of Hib vaccines.
Sections du résumé
BACKGROUND
Haemophilus influenzae type b (Hib) vaccine is effective in reducing the burden of Hib related diseases, but little is known about factors influencing the uptake of Hib vaccine. This study aimed to assess the uptake of Hib vaccination and its associated factors in Shanghai City, China.
METHODS
We used data from a retrospective cohort of 183,246 children born in 2012-2016 obtained from the Shanghai Immunization Program Information System, which provided information on the uptake of Hib vaccination. We conducted a cross-sectional study of 451 children to collect information on demographic and other factors that might be associated with Hib vaccination.
RESULTS
In the retrospective cohort study, the proportions of Hib dose-1 coverage, vaccination completion and timeliness were 67.7, 52.2 and 29.4%, respectively. These measures were better among local children and increased with birth year, while there were regional differences. Hib vaccine uptake was significantly associated with maternal occupation (non-health vs health workers, OR = 2.33, 95% CI: 1.32-4.13, P = 0.004) and caregivers' awareness of Hib (yes vs no, OR = 1.75, 95% CI: 1.12-2.74, P = 0.013).
CONCLUSIONS
We found low levels of coverage of dose-1 Hib vaccine, timeliness and completion, suggesting inadequate protection against Hib disease for children in Shanghai. Non-local children and those of health workers should be targeted for interventions. The inclusion of Hib vaccine into the national immunization program could help improve the uptake of Hib vaccines.
Identifiants
pubmed: 30616637
doi: 10.1186/s12887-018-1374-6
pii: 10.1186/s12887-018-1374-6
pmc: PMC6323772
doi:
Substances chimiques
Haemophilus Vaccines
0
Haemophilus influenzae type b polysaccharide vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Références
Vaccine. 2010 Feb 3;28(5):1264-74
pubmed: 19941996
Lancet. 2009 Sep 12;374(9693):903-11
pubmed: 19748399
Vaccine. 2005 May 2;23(24):3103-7
pubmed: 15837208
Vaccine. 2017 Nov 1;35(46):6275-6282
pubmed: 28987442
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Vaccine. 2018 May 31;36(23):3351-3358
pubmed: 29716777
Wkly Epidemiol Rec. 2013 Sep 27;88(39):413-26
pubmed: 24143842
Vaccine. 2014 Feb 12;32(8):944-8
pubmed: 24397901
Vaccine. 2018 Jan 25;36(4):545-552
pubmed: 29233605
Pediatrics. 2011 May;127 Suppl 1:S107-12
pubmed: 21502236
Vaccine. 2004 Jan 2;22(3-4):378-82
pubmed: 14670319
Lancet Glob Health. 2016 Mar;4(3):e185-94
pubmed: 26853149
Epidemiol Infect. 2013 Sep;141(9):1787-96
pubmed: 23425638
Lancet Infect Dis. 2010 May;10(5):317-28
pubmed: 20417414
PLoS One. 2014 May 14;9(5):e97800
pubmed: 24828814